Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31048086 | 1.00 | TSHR (0.37) | TSHRARPDE4APDE4BPDE4C | |
| SCHEMBL2648450 | 0.84 | BACE1 (0.32) | TSHRAR | |
| SCHEMBL31448668 | 0.84 | TSHR (0.35) | TSHRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL21083818 | 0.81 | CYP11B1 (0.38) | ARKDM4EALDH1A1HTT | |
| SCHEMBL29593052 | 0.80 | TSHR (0.39) | TSHRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7164061 | 0.80 | TSHR (0.39) | TSHRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL12299446 | 0.80 | POLB (0.32) | ARPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2187689 | 0.80 | LATS1 (0.35) | HTT | |
| SCHEMBL2659671 | 0.80 | CA1 (0.34) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL21635295 | 0.80 | AR (0.32) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7037905-B2 | Pharmaceutical use of boronic acids and esters thereof | NOVO NORDISK A/S (DK) | 2006-05-02 | — | — | US | claimed |
| US-20040053889-A1 | Pharmaceutical use of boronic acids and esters thereof | NOVO NORDISK A/S (DK) | 2004-03-18 | — | — | US | claimed |
| WO-2003105860-A1 | PHARMACEUTICAL USE OF BORONIC ACIDS AND ESTERS THEREOF | NOVO NORDISK A/S (DK) | 2003-12-24 | — | — | WO | claimed |
| US-6559310-B2 | Reacting a halogen aromatic derivative at a coupling position with a diboron derivative in the presence of a Group VIII metal catalyst and a suitable base for covalently coupling organic compounds | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2003-05-06 | — | — | US | claimed |
| US-20020193604-A1 | Aryl borates | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2002-12-19 | — | — | US | claimed |
| EP-0986541-A4 | PROCESS FOR COVALENTLY COUPLING ORGANIC COMPOUNDS UTILIZING DIBORON DERIVATIVES | COMMW SCIENT IND RES ORG (AU) | 2002-08-14 | — | — | EP | claimed |
| US-20020032339-A1 | ARYL BORATES | BORON MOLECULAR LIMITED (AU) | 2002-03-14 | — | — | US | claimed |
| EP-0986541-A1 | PROCESS FOR COVALENTLY COUPLING ORGANIC COMPOUNDS UTILIZING DIBORON DERIVATIVES | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2000-03-22 | — | — | EP | claimed |
| WO-1998045265-A1 | PROCESS FOR COVALENTLY COUPLING ORGANIC COMPOUNDS UTILIZING DIBORON DERIVATIVES | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 1998-10-15 | — | — | WO | claimed |
| EP-4539855-A1 | BORON CONTAINING PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS AND USES THEREOF | Borah, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| US-12145927-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-11-19 | — | — | US | disclosed |
| EP-3035929-B1 | 7A-AMIDE SUBSTITUTED-6,6-DIFLUORO BICYCLIC HIMBACINE DERIVATIVES | MERCK SHARP & DOHME LLC (US) | 2024-07-03 | — | — | EP | disclosed |
| WO-2023244775-A1 | BORON CONTAINING PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS AND USES THEREOF | Boehringer Ingelheim Animal Health USA Inc. (US) | 2023-12-21 | — | — | WO | disclosed |
| WO-2023283831-A1 | VIRUS MAIN PROTEASE INHIBITOR, PREPARATION METHOD THEREFOR, AND USE | 上海药明康德新药开发有限公司 | 2023-01-19 | — | — | WO | disclosed |
| US-20060189577-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2006-08-24 | — | — | US | disclosed |
| EP-1651599-A1 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2006-05-03 | — | — | EP | disclosed |
| US-7037905-B2 | Pharmaceutical use of boronic acids and esters thereof | NOVO NORDISK A/S (DK) | 2006-05-02 | — | — | US | disclosed |
| WO-2005009957-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20040053889-A1 | Pharmaceutical use of boronic acids and esters thereof | NOVO NORDISK A/S (DK) | 2004-03-18 | — | — | US | disclosed |
| WO-2003105860-A1 | PHARMACEUTICAL USE OF BORONIC ACIDS AND ESTERS THEREOF | NOVO NORDISK A/S (DK) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189577-A1 | Tyrosine kinase inhibitors | ABL1, RET, ERBB2 | TSHR 456/4885AR 1244/4885PDE4A 1396/4885 |
| US-20040053889-A1 | Pharmaceutical use of boronic acids and esters thereof | LIPE, CEL, LIPA | TSHR 315/4885AR 1526/4885PDE4A 324/4885 |
| US-20020193604-A1 | Aryl borates | BRD4, ABL1, BRD3 | TSHR 2306/4885AR 1381/4885PDE4A 4174/4885 |
| US-12145927-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | IDO1, IDO2, INMT | TSHR 3165/4885AR 2460/4885PDE4A 1607/4885 |
| US-20020032339-A1 | ARYL BORATES | TBCB, HAT1, UBE2B | TSHR 2491/4885AR 1296/4885PDE4A 4225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.